The FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, announced in June 2025, aims to dramatically reduce review times for drug and biological products to just one to two months—down from the typical six months or more. The initiative introduces a collaborative "tumor board" style review process designed to fast-track priority treatments.
The program is intended to expedite the review of certain drug and biological product applications, though specific eligibility criteria and candidate indications were not detailed in the announcement. This represents a significant departure from traditional FDA review workflows, merging expert panels for faster decision-making.
The CNPV pilot could reshape regulatory timelines for breakthrough therapies, potentially bringing life-saving drugs to market months earlier. However, the program's scope remains limited, and it is not yet clear how many applications will qualify or how the voucher system will be allocated among sponsors.
For the pharmaceutical industry, the pilot introduces both opportunity and uncertainty. Shorter review cycles may reduce development costs and speed patient access, but the compressed timeline raises questions about data integrity and the ability of sponsors to prepare robust submissions on an accelerated schedule.
Critics warn that the rush could increase the risk of incomplete reviews or overlooked safety signals. Without clear guardrails, the program might favor well-resourced companies, leaving smaller biotechs struggling to meet the new pace."